Together with our colleagues, we proposed the now universally accepted classification and nomenclature of the PI3K isoforms [1, 2]
We have reviewed the PI3K field on numerous occasions (see amongst others: [2-14] below)
Together with Dr. Pedro Cutillas at Queen Mary University of London, we set up Activiomics Ltd. (2010) to develop biomarkers in disease using mass spectrometry techniques. In March 2014, Activiomics was acquired by Retroscreen Virology (now hVIVO).
References
Zvelebil, M.J., et al., Structural and functional diversity of phosphoinositide 3-kinases. Philos Trans R Soc Lond B Biol Sci, 1996. 351(1336): p. 217-23.
Vanhaesebroeck, B., et al., Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci, 1997. 22(7): p. 267-72.
Vanhaesebroeck, B. and Alessi, D.R., The PI3K-PDK1 connection: more than just a road to PKB. Biochem J, 2000. 346 Pt 3: p. 561-76.
Vanhaesebroeck, B., et al., Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem, 2001. 70: p. 535-602.
Okkenhaug, K. and Vanhaesebroeck, B., PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol, 2003. 3(4): p. 317-30.
Vanhaesebroeck, B., et al., Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci, 2005. 30(4): p. 194-204.
Okkenhaug, K., Ali, K. and Vanhaesebroeck, B., Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol, 2007. 28(2): p. 80-7.
Kok, K., Geering, B. and Vanhaesebroeck, B., Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci, 2009. 34(3): p. 115-27.
Vanhaesebroeck, B., et al., The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol, 2010. 11(5): p. 329-41.
Vanhaesebroeck, B., Stephens, L., and Hawkins, P., PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol, 2012. 13(3): p. 195-203.
Vanhaesebroeck, B., Whitehead, M.A. and Piñeiro, R., Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med, 2016.
PI3K isoforms in cell signalling and vesicle trafficking. Bilanges B, Posor Y, Vanhaesebroeck B. Nat Rev Mol Cell Biol. 2019 Sep;20(9):515-534. doi: 10.1038/s41580-019-0129-z.
Cracking the context-specific PI3K signaling code. Madsen RR, Vanhaesebroeck B. Sci Signal. 2020 Jan 7;13(613):eaay2940. doi: 10.1126/scisignal.aay2940.
PI3K inhibitors are finally coming of age. Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. Nat Rev Drug Discov. 2021 Oct;20(10):741-769. doi: 10.1038/s41573-021-00209-1.
Close
